Drug Profile
DS 1150
Alternative Names: DS-1150bLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Inc
- Class Antihyperlipidaemics
- Mechanism of Action GLUT4 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 31 Oct 2013 Daiichi Sankyo completes a phase I trial in Type-2 diabetes mellitus in USA (NCT02004678)
- 30 Sep 2013 Phase-I clinical trials in Type-2 diabetes mellitus in USA (PO)